We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Effect of Lipoprotein(A) on the Diagnosis of Familial Hypercholesterolemia

By LabMedica International staff writers
Posted on 25 Nov 2019
Print article
Image: The Architect clinical chemistry autoanalyzer C16000 (Photo courtesy of Abbott Diagnostics).
Image: The Architect clinical chemistry autoanalyzer C16000 (Photo courtesy of Abbott Diagnostics).
The recent focus on familial hypercholesterolemia (FH) as a high-risk condition predisposing to premature coronary artery disease (CAD) has led to more widespread screening and diagnosis of the condition. Familial hypercholesterolemia is a genetic disorder.

FH is caused by a defect on chromosome 19. The defect makes the body unable to remove low density lipoprotein (LDL) cholesterol from the blood. Diagnostic tools for familial hypercholesterolemia (FH) rely on estimation of LDL cholesterol concentration. However, routine measurement or calculation of LDL cholesterol concentration using the Friedewald equation contains a cholesterol contribution from lipoprotein(a) [Lp(a)].

Medical Scientists from the University of Western Australia (Perth, Australia) undertook a cross-sectional study of adult index patients aged >18 years with or without a recognized mutation causative of FH. Data on Lp(a) concentrations were available in 907 patients suspected of FH. The Dutch Lipid Clinic Network (DLCN) and Simon Broome (SB) diagnostic criteria were estimated before and after adjusting LDL cholesterol concentration for the cholesterol content (30%) of Lp(a).

All biochemical measurements were performed with routine assays in an accredited laboratory. LDL cholesterol was estimated by the Friedewald equation; with triglyceride >400 mg/dL (4.5 mmol/L) (n = 4), LDL cholesterol was measured by direct assay. LDL cholesterol was adjusted for statin therapy in individuals receiving therapy to establish the phenotypic diagnosis of FH. Lp(a) was measured by an automated latex enhanced immunoassay, the Quantia Lp(a) assay, (Abbott Laboratories, Abbott Park, IL, USA). Briefly, the Quantia Lp(a) is a turbidimetric immunoassay using monoclonal antibody for the estimation of Lp(a) in human serum or plasma in an Abbott Diagnostics Architect autoanalyzer C16000 and is based on the principle of an agglutination reaction.

The investigators reported that 74 patients defined by DLCN criteria (8.2%) and 207 patients defined by SB criteria (22.8%) were reclassified to “unlikely” FH after adjusting LDL cholesterol for Lp(a) cholesterol. The proportion of FH patients defined by DLCN (probable/definite) and SB (possible/definite) criteria decreased significantly in patients with increased Lp(a) (>0.5 g/L; n = 330) after Lp(a) cholesterol adjustment. The overall reclassification rate was significantly higher in patients with Lp(a) concentration >1.0 g/L. The AUROC curve for LDL cholesterol concentration ≥191 mg/dL (≥5.0 mmol/L), DLCN criteria, and SB criteria in predicting an FH mutation increased significantly after adjustment. There was no significant difference in AUROC curve before and after Lp(a) cholesterol adjustment at an LDL cholesterol concentration ≥251 mg/dL (≥6.5 mmol/L).

The authors concluded that adjusting LDL cholesterol concentration for Lp(a) cholesterol improves the diagnostic accuracy of DLCN and SB criteria, especially with Lp(a) >1.0 g/L and LDL cholesterol <251 mg/dL (<6.5 mmol/L). Lp(a) should be measured in all patients suspected of having FH. The study was published in the October, 2019 issue of the journal Clinical Chemistry.

Related Links:
University of Western Australia
Abbott Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.